200
Participants
Start Date
October 23, 2019
Primary Completion Date
August 18, 2024
Study Completion Date
October 23, 2027
Palbociclib
"The included patients will first receive the following systemic treatment according standard of care:~* Non-steroidal aromatase inhibitor (letrozole)~* Palbociclib~* Monthly Luteinizing hormone-releasing hormone (LHRH) analogue for non-menopausal patients only. Surgical bilateral oophorectomy is an acceptable option."
locoregional treatment
After normally 6 courses of systemic treatment initiation, the loco-regional treatment of the primary tumour will be performed: surgery (conservative or mastectomy) with or without radiotherapy, or radiotherapy
Hôpital St Joseph, Marseille
Institut Paoli Calmettes, Marseille
Centre George François Leclerc, Dijon
Institut Claudius Regaud, Toulouse
Hôpital saint Eloi CHU Montpellier, Montpellier
ICM Val d'Aurelle, Montpellier
Centre Eugène Marquis, Rennes
Hôpital Privé à Saint Grégoire, Saint-Grégoire
Institut de Cancérologie de l'Ouest-Site Paul Papin, Angers
CH Cholet, Cholet
Institut Jean Godinot, Reims
Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy
Centre Jean Perrin, Clermont-Ferrand
Centre Hospitalier de Pau, Pau
Centre Léon Bérard, Lyon
Hôpital privé sainte Marie, Chalon-sur-Saône
Institut Curie Site Paris, Paris
Hôpital Saint Louis APHP, Paris
Hôpital St Joseph, Paris
Hôpital Tenon, Paris
Institut Sainte Catherine, Avignon
Institut Curie Hôpital René Huguenin, Saint-Cloud
Gustave Roussy, Villejuif
CH René Dubos, Pontoise
GCS RISSA - Institut de cancérologie Paris Nord, Sarcelles
Centre François Baclesse, Caen
Collaborators (1)
Pfizer
INDUSTRY
UNICANCER
OTHER